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Patients with chronic kidney disease (CKD) experience imbalance between oxygen reactive species (ROS) production and
antioxidant defenses leading to cell and tissue damage. However, it remains unclear at which stage of renal insufficiency the
redox imbalance becomes more profound. The aim of this systematic review was to provide an update on recent advances in our
understanding of how the redox status changes in the progression of renal disease from predialysis stages 1 to 4 to end stage 5 and
whether the various treatments and dialysis modalities influence the redox balance. A systematic review was conducted searching
PubMed and Scopus by using the Cochrane and PRISMA guidelines. In total, thirty-nine studies met the inclusion criteria and
were reviewed. Even from an early stage, imbalance in redox status is evident and as the kidney function worsens it becomes
more profound. Hemodialysis therapy per se seems to negatively influence the redox status by the elevation of lipid peroxidation
markers, protein carbonylation, and impairing erythrocyte antioxidant defense. However, other dialysis modalities do not so far
appear to confer advantages. Supplementation with antioxidants might assist and should be considered as an early intervention to
halt premature atherogenesis development at an early stage of CKD.
1. Introduction
In the literature there is strong evidence suggesting that
uremia, which develops in tandemwith renal deterioration, is
accompanied by an enhanced state of oxidative stress, which
in turn is associated with higher risk of developing cardio-
vascular disease (CVD) and mortality [1]. The presence of
oxidative stress in uremic patients is manifested by increases
in the levels of several oxidative damage markers and by a
parallel reduction in their antioxidant defense capacity [2, 3].
In chronic kidney disease (CKD), this state of redox imbal-
ance is linked to additional pathological complications that
CKDpatients presentwith, such asmalnutrition, anemia, and
cardiovascular disease including atherosclerosis [2, 4, 5].
CVD remains the leading cause of death in CKD patients,
with oxidative stress being implicated in the onset and the
development of atherosclerosis, via mechanisms such as oxi-
dation of low density lipoprotein (LDL) [6]. It is reported that
levels of lipid and protein peroxidation markers, such as mal-
ondialdehyde (MDA), advanced glycosylation end product
(AGE), and advanced oxidation protein products (AOPPs),
are elevated in CKD patients, with some studies indicating
a correlation between some lipid peroxidation markers and
intima-media thickness [7–9]. Lipid peroxidation could be
described as a process where oxidants, such as free radicals,
assault lipids especially in membranes [10]. Additionally,
regarding erythrocytemembrane integrity,modifications due
to oxidation and the increased membrane rigidity could play
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a key role in shortening erythrocyte half-life compound-
ing the development of anemia [11], which characterizes
these patients. Furthermore, a disturbance of the glutathione
antioxidant system, including overall compromised blood
levels of reduced glutathione (GSH), increased oxidized
glutathione (GSSG), and increased erythrocyte glutathione
peroxidase (GPx) and glutathione reductase (Gr reductase)
activities, has been reported in CKD [12, 13]. Likewise, a
decrease in catalase (CAT), a key enzyme for the detoxi-
fication of hydrogen peroxide and organic hydroperoxide,
accompanied by increased nitric oxide (NO) inactivation and
protein nitration by reactive oxygen species (ROS) [14], has
been linked to the pathogenesis of CKD related hypertension
via a dysregulation of NO function. Further, at the level of
the kidney per se, redox disturbances can have direct effects
on the afferent arteriole function (e.g., vasoconstriction) and
tubuloglomerular feedback (e.g., affecting macula densa cell
function or signaling), contributing to the development of
hypertension [15].
A variety ofmechanisms have been implicated in the gen-
eration of oxidative stress in uremic patients, such as antiox-
idant deficiency and chronic inflammation [16, 17] including
advanced glycation mediated disturbances of glomerular
homeostasis as disease progresses [18]. In addition, for the
end stage renal disease (ESRD) patients, neutrophil activation
during hemodialysis (HD) therapy [19] and dialysis treatment
per se contribute to the increase of oxidative damage observed
in patients with CKD [20–22]. Four main factors have been
proposed to be responsible for the harmful effects of oxidative
stress in patients under HD: the uremic milieu, the HD
treatment per se, the hemoincompatibility of dialysis system,
and the concomitant drug treatment [23].
Until today most studies examining the redox status
in CKD patients focused on the end stage of the disease.
However, it remains unclear when during disease progression
the redox imbalance manifests itself and which one of
its components, defense capacity or ROS overproduction,
becomes critical first. Thus the aim of this systematic review
was to provide an update on recent advances in our under-
standing of how the redox status changes in the progression
of CKD from predialysis stages (1 to 4) to end stage 5 and
whether various treatments positively or negatively influence
the balance between oxidant and antioxidant mechanisms.
2. Methods
The current review includes original studies reporting on
oxidative stress markers in CKD patients (including pre-
dialysis and ESRD, on hemodialysis or peritoneal dialysis).
PubMed and Scopus databases were searched by two review-
ers according to the Cochrane and PRISMA guidelines [24,
25] in order to identify publications in English related to
oxidative stress in blood of uremic patients. A comprehensive
literature search was conducted from September 2015 until
November 2015. The time frame the studies were searched
was from January 1995 until November 2015. Studies were
selected using inclusion and exclusion criteria. We included
studies thatmet the following criteria: they assessed oxidative
stress markers in the blood of uremic patients (hemodialysis,
peritoneal dialysis, or predialysis); they used blood samples;
they addressed randomized control trials, controlled trials,
or clinical trials designed to evaluate oxidative stress in
blood of uremic patients on HD and PD therapy or not;
they were written in English. Exclusion criteria included
the following: studies of patients with untreated cardio-
vascular disease, metabolic syndrome, hyperparathyroidism
and hypertension, kidney transplantation, atherosclerosis,
and cancer. Moreover, case studies, dissertations, letters,
studies published only in abstract form, and studies that
were unavailable in English were excluded from the analysis
as well. Firstly, titles and abstracts were assessed, followed
by assessment of full-text copies of the articles. The initial
screening was followed by an extra search in order to identify
only the studies that dealt with oxidative stress in uremic
patients.
3. Overall Results
The literature search identified a total of 80 articles. Of these,
39 studies met the inclusion criteria, which were set in this
review (Figure 1). Articles were excluded for the following
reasons: 23 studies correlated CKD with factors which were
irrelevant to oxidative stress and thus were out of our interest
or dealt mainly with other comorbidities such as diabetes,
cardiovascular disease, and hyperparathyroidism. One study
examined acute chronic liver disease instead of CKD. Seven
studies did not measure oxidative stress biomarkers, to three,
despite efforts, we gained no access, one was nonrandomized
study, one was not written in English, and 5 did not have
detailed methodology.
From the included studies, three evaluated oxidative
stress markers in blood of predialysis patients compared to
healthy individuals and four studies dealt with several types of
interventions in these patients. Ten studies examined oxida-
tive stress in HD patients compared to healthy individuals
and eight studies assessed oxidative stress before and afterHD
session. Seven studies reported some interventions affecting
the redox status of HD patients. Two studies examined oxida-
tive stress biomarkers in patients undergoing other types of
HD and one study reported an intervention that took place in
these patients. One study examined simultaneously oxidative
stress in predialysis, HD dialysis, and PD dialysis compared
to healthy individuals. One study examined oxidative stress
markers in predialysis patients compared to controls, in HD
patients compared to controls, and in HD patients before and
after an HD session. Two studies evaluated oxidative stress in
HD patients compared to controls and in HD patients before
and after an HD session. For these reasons data from these
last four studies were included in more than one Table.
4. Analysis and Discussion
We used the CKD severity staging reported by the authors
themselves, or when not available, to facilitate discussion,
we adopted the definition of CKD stages based on measured
or estimated Glomerular Filtration Rate (GFR), according to
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Figure 1: Progress of the literature screening.
KDIGO 2012 guidelines for CKD [26]. According to these
guidelines, there are five stages, where kidney function is
considered as normal in stage 1 and is progressively reduced
as progressing from stages 2 to 5. Each section reporting
on the analysis of our systematic review’s findings concludes
with discursive commentary using relevant information from
other literatures.
4.1. Predialysis Patients and Redox Status. Only 5 studies
examined the redox status in predialysis CKD patients.These
studies evaluated the oxidative damage as it was assessed by
the lipid peroxidation biomarker MDA and the prooxidant
enzyme xanthine oxidase (XO) as well as the antioxidant
defense as it was assessed by GSH concentration and super-
oxide dismutase (SOD) and CAT andGPx activities (Table 1).
Regarding lipid peroxidation damage, four studies mea-
sured MDA levels in plasma or red blood cells (RBC) of
CKD patients. Specifically, Peuchant et al. 1996 [11] found
increased levels of RBC-free MDA in 16 patients with stage
5 CKD compared to age-matched controls. Additionally,
Sahni et al. [27] found increased RBC MDA levels in 60
patients with severe CKD (near stage 5) and in 85 patients
withmoderate CKD compared to age-matched controls, with
RBC MDA levels being significantly higher in the severe
compared to moderate disease group. MDA levels were also
evaluated in plasma and Papavasiliou et al. [28] found them
increased in 23 patients with stages 3–5 CKD, compared
to age-matched controls. In the same study 13 patients on
stages 1-2 CKD exhibited a tendency for higher MDA levels
compared to healthy controls but values’ differences did not
reach statistical significance. In contrast, patients with stages
1-2 exhibited significantly lower MDA levels compared to the
patients with stages 3–5 CKD [28]. Bober et al. 2010 [29],
measuring TBARS (which are expressed as equivalents of
MDA levels), reported higher plasma levels in 21 predialysis
CKD patients on conservative treatment and age-matched
healthy controls. However, it was not clear if results were
statistically significant nor was there information on the
predialysis stage of those patients. Choi et al. [30] reported
that xanthine oxidase (XO) activity was increased in the
plasma of 16 patients with stage 4 CKD (almost ∼1.5-fold
compared to values of healthy individuals), indicating an
increase in free radicals generation.
Regarding antioxidant defense in predialysis patients,
four studies evaluated several antioxidant molecules and
enzymes. Sahni et al. 2012 [27] found that the increase in
lipid peroxidation biomarkers in predialysis patients was
accompanied by a reduction in antioxidant enzymes activity
being reflected by reduced GSH, SOD, and CAT levels in
both severe and moderate predialysis patients, compared to
healthy individuals [27]. On the other hand, in the study of
Bober et al. [29], higher levels of GSH were found in CDK
patients compared to healthy individuals but as it was referred
above the stage of patients’ disease was not mentioned in the
study. However, a study by Peuchant et al. [11] did not observe
any changes in the activities of the free radical scavenging
enzymes GPx, SOD, and CAT in the erythrocytes of CKD
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patients compared to healthy individuals. Significantly higher
levels of erythrocytes GPx activity have also been observed in
both patients with stages 1-2 and stages 3–5CKD compared to
healthy subjects, by Papavasiliou et al. [28], with EPO treat-
ment preventing the reduction in enzyme activity observed
in patients not receiving EPO.
The results of these five studies concur to the fact that
CKD progression leads gradually to a state of increased ROS
production, which is reflected by the elevated levels in mark-
ers of lipid damage and the decrease in the concentration of
antioxidant molecules and activity of antioxidant enzymes.
As mentioned already, lipid peroxidation affects erythrocyte
half-life, as its excess could overcome cell repair capacity
[10]. According to Peuchant et al. [11], their results could be
attributed to the fact that patients with CKD have decreased
erythrocytes survival. Thus erythropoiesis is activated and
could increase RBC precursors and enzymatic synthesis
as well as consumption of antioxidant enzymes. Moreover,
additional mechanisms are implicated in the enhanced lipid
peroxidation in CKD such as the reduction in glucose-6-
phosphate dehydrogenase activity, which leads to a decrease
inNADPHandGSHconcentrations and vitaminEdeficiency
[31–33].
Undeniably, a compromised antioxidant intake may con-
tribute to the above observations, as predialysis patients
need to adhere to specific diet guidelines and restrictions
[27]. Indeed, intake of exogenous antioxidant vitamins, such
as vitamins A and C, and glutathione precursors were
found to be at lower levels in predialysis patients compared
to healthy subjects, with nutritional intakes worsening as
CKD became more severe and evident negative correlations
between antioxidant intakes with oxidative stress levels [27].
4.2. Interventions in Predialysis Patients and Redox Sta-
tus. Several interventions to correct for anemia, counteract
inflammation, and supplement nutrition have become part
of clinical and periclinical care in addition to appropriate
pharmacological therapy and could affect redox balance. At
the predialysis stage we located only four references that
fulfilled our criteria.
Ganguli et al. [34] reported that various forms of intra-
venous iron [lowmolecular weight iron dextran (ID), sodium
ferric gluconate complex, in sucrose (SFGC), and iron sucrose
(IS)] at clinically used doses resulted in elevated MDA levels,
measured immediately after the iron transfusion period [34].
Marsillach et al. [35] evaluated the 6-month effects of EPO
treatment together with iron treatment (SFGC or IS), mea-
suring antibodies against ox-LDL and paraoxonase (PON1)
activity and concentration which is assumed to play an
important role in oxidized lipid degradation. Results revealed
decreased levels of ox-LDL antibodies and increased serum
PON1 activity despite the iron treatment [35]. However, in
addition to an effect of EPO, large differences in baseline
LDL and ferritin levels between the two studied cohorts can
explain the conflicting reports.
Ramos et al. [36] investigated whether the administration
of mixed tocopherols and lipoic acid for 2 months could
modify oxidative stress indices in CKD patients. However,
no significant changes in F2-isoprostanes and protein thiols
concentrations were observed in these patients compared
to matching controls. As the authors discussed, the sample
size, the intervention’s duration, the dose, or the composition
of antioxidants all could probably have been biologically
ineffective in altering the redox status of this particular
patient population [36]. Moreillon et al. [37] assessed the
antioxidant effects of two types of herbal supplements cur-
cumin and Boswellia serrata, on GPx levels, after 8-week
supplementation.Despite the increase in plasmaGPx levels in
the treatment group, results were not statistically significant.
Perhaps the duration of supplementation was not sufficient
enough for the small sample size used [37] to detect an effect.
Data in non-CKD patients suggest that higher doses of
vitamin E supplementationmay be necessary to observemea-
surable changes in redox status. For example, in hypercholes-
terolemia patients, after 4 months of vitamin E supplemen-
tation, there was a decrease in F2-isoprostane concentration,
only with the high doses of 1600 and 3200 IU/day [38]. Herbal
supplements such as curcumin [39] and Boswellia serrata [40,
41] are known for their anti-inflammatory and antioxidant
characteristics, for example, in patients with colitis [40, 41].
While one study [37] did not report an effect, future studies
could explore further their possible contribution to amelio-
rate oxidative stress in predialysis patients via nutritional
strategies.
Apart from the impaired nutritional status, CKD patients
are also characterized by iron deficiency and depletion of
iron storage. Although the administration of intravenous
iron is fully recommended in these patients for anemia
correction, the short-term safety and long-term safety of
this administration remain unclear. According to Bishu and
Agarwal [42] intravenous iron administration contributes
to elevated oxidative stress and endothelial dysfunction in
CKDpatients.Moreover, according toHimmelfarb et al. [43],
endothelial dysfunction plays a key role in the pathogenesis
of atherosclerosis in CKD patients and oxidative stress is
implicated in this pathway. It can be surmised that a treatment
meant to correct anemia and iron supplementation could
exacerbate atherosclerosis by promoting oxidative stress.
The two studies supplementing iron to predialysis patients
reviewed above, Ganguli et al. [34] and Marsillach et al.
[35], reported conflicting effects of iron on lipid peroxida-
tion. However, the interaction of iron to circulating LDL
cannot be underestimated (i.e., a systemically atherogenic
environment), while at the same time EPO appears to confer
an antioxidant advantage (as shown earlier by Papavasiliou
et al. [28] that EPO treatment prevented the reduction in
erythrocytes GPx activity observed in patients not receiving
EPO).
4.3. HD Patients and Redox Status. Overall, 14 studies were
found, which examined the oxidant and antioxidant status
in HD patients and compared them with healthy subjects
(Table 2). These studies evaluated oxidative damage as it
was assessed by lipid peroxidation markers MDA and iso-
prostanes and protein carbonylation as it was assessed by
protein carbonyls and advanced oxidation protein products
6 Oxidative Medicine and Cellular Longevity
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(AOPPs). Moreover, in these studies, the antioxidant defense
was evaluated by measuring the antioxidant molecules
sulfhydryl groups and GSH, the antioxidant enzymes SOD,
GPx, and Gr reductase, and the total antioxidant capacity
markers oxygen radical absorbing capacity (ORAC), trolox
equivalent antioxidant capacity (TEAC), and total antioxi-
dant capacity (TAC).
More specifically, in seven studies, increased levels of
MDA [29, 44–49] were observed in HD patients compared
to healthy individuals, reflecting extensive lipid damage.
Sommerburg et al. [44] reported that HD patients who
received long-term EPO treatment showed decreased levels
of lipid peroxidation compared to patients who did not
receive EPO treatment. Furthermore, Dolegowska et al. [50]
reported a significant increase in plasma isoprostanes (8-
iPF2a-III) concentrations in HD patients.
Regarding protein damage, levels of protein carbonyls
were also found to be elevated in HD patients in four studies
[49, 51–53]. In addition, advanced oxidation protein products
(AOPPs) were found to be in high levels in HD patients in
two studies [46, 53]; however, they were reported to be no
different from control in one study [54]. In the latter study of
Fragedaki et al. [54], patients were on dialysis for a shorter
period (an average of 3 years) than the other studies [46, 53],
a fact that could affect AOPPs levels. Finally, Choi et al. [30]
reported increased XO activity in HD patients compared to
healthy subjects (by almost 3 times), with XO activity being
also higher (by 2.1 times) than predialysis patients. Taking
into consideration the above results, there is evidence of
extensive oxidative damage to total protein content and lipids
in HD patients.
Regarding the antioxidant capacity in HD patients, the
literature provides differing results. Sakata et al. reported a
significant increase in “global” antioxidant capacity mark-
ers, such as ORAC and TEAC [46]. On the other hand,
Dimitrijevic et al. [47] reported a significant decrease in
total antioxidant capacity (TAC) of HD patients compared to
controls, while decreased albumin levels were also observed.
It should be noted that these global antioxidant capacity
markers do not represent innate antioxidant capacity but
rather represent global availability of free radical scavenging
compounds, whose levels are greatly affected by nutrition.
Moreover, the activity of the free radical scavenging
enzymes plasma GPx (GSH-Px) and SOD was found to be
significantly decreased in HD patients [48]. GPx has been
identified in two forms, cellular or cytosolic (GPx-1), which
is presented in red blood cells and the cytosol of almost all
tissues, and extracellular (GPx-3) in the plasma, with sele-
nium (Se) being a basic structural component in both forms,
[48], an element also affected by nutrition. Additionally, Gr
reductase activity was found to be significantly higher in
HD patients compared to healthy subjects [55], probably
reflecting the organism’s efforts to activate the antioxidant
defenses. Likewise, that study also reported increased GSH
total blood concentrations in the HD patients studied [55].
On the other hand, two studies [47, 53] reported a large
reduction of free sulfhydryl groups’ levels in HD patients,
measured in plasma.
All the results concur to the fact that HD treatment seems
to contribute to augmented oxidative stress. Most of the
studies observed increased levels of protein and lipid damage
in HD patients, which were measured with established
biomarkers. As it appears, HD treatment causes an enhanced
rate of LDL oxidation, which leads to the development of
atherosclerosis, as reflected in elevated blood MDA levels.
One mechanism is that the uremic milieu and the HD
process per se stimulate neutrophils, a procedure known as
“neutrophil burst,” which directly or indirectly results in
hydrogen peroxide production. This is then converted to
hypochlorous acid, which in turn contributes to the oxidation
of plasma proteins and LDL, assaulting their membranes [46,
56]. Furthermore, as it was referred above, lipid peroxidation
negatively affects erythrocyte half-life leading to decreased
survival and manifestation of anemia. EPO appears to help
as Sommerburg et al. [44] reported that HD patients who
received long-term EPO treatment had decreased levels of
lipid peroxidation. These results in HD concur with findings
in predialysis patients, where also EPO appears to confer an
antioxidant advantage [28], by preventing the reduction in
erythrocytes GPx activity observed in patients not receiv-
ing EPO. Moreover, while erythropoiesis is, in a healthy
individual, stimulated by ROS, as discussed by Migliaccio,
erythropoiesis also counteracts circulating ROS levels via
increases in available catalase and possibly other antioxidant
enzymes [57]. Further, on the atherosclerosis mechanism,
the presence of F2-isoprostanes has been determined in
human atherosclerotic lesions [58]. F2-isoprostanes are cre-
ated during the nonenzymatic peroxidation of arachidonic
acid bound up with phospholipids of cells membranes and
lipoproteins [59–61], and they are considered sensitive and
specific indicators of oxidative stress intensity in vivo [58, 62].
Given reports, such as [50], of a significant increase in plasma
isoprostanes in HD patients, the link between oxidative stress
and CVD in HD patients is further highlighted.
The results on the antioxidant capacity of HD patients
are not as straightforward to explain. Caloric restriction
(without essential nutrient deficiency) in rats has been shown
to result in decreased antioxidant capacity (ORAC) [63].
CKD patients, however, are subject to both caloric restriction
and deficient antioxidant intakes [23]. Differences between
studies reporting on HD antioxidant capacity could be thus
attributed not only to adaptive mechanisms, due to years in
dialysis and comorbidities, but also to dietary restrictions and
interindividual differences in antioxidant nutritional intakes,
as already reported in predialysis patients [27].
Additionally, the hemodialysis process per se may com-
promise key nutrient and trace mineral levels as highlighted
with regard to levels of Se, a basic component of GPx. Guo
et al. [48] reported that HD patients presented with lower
plasma Se concentrations than healthy subjects and this could
be attributed to either impaired diet/absorption or increased
loss of Se during dialysis treatment [64]. Additionally, taking
into account the fact that the kidney is themain site of plasma
GPx synthesis and is also capable of Se accumulation [65], the
fact that the levels of both Se and GPx are reduced in ESRD
patients is not unexpected. A similar explanation could be
also given for the significant reduction in plasma SODactivity
10 Oxidative Medicine and Cellular Longevity
observed in HD patients, linked to Zn availability, which is a
structural element of SOD and whose levels tend also to be
reduced in renal insufficiency [66].
Regarding GSH depletion in HD patients, many mech-
anisms have been proposed. According to Yawata and Jacob
[31], an obstruction to the pentose phosphate pathway leading
to impaired production of NADPH occurs in patients with
ESRD. As a result, Gr reductase cannot recycle GSSG back to
GSHusingNADPHas electron source [31]. Notwithstanding,
in many studies, GR activity has been found to be increased
or to be in normal levels [12, 55, 67, 68]. Thus, GSH
depletion could be alternatively attributed to a diminished
GSH synthesis and/or to an increasedGSHdegradation, since
its precursors cystine, glutamate, and glycine could be normal
or could be elevated in patients’ blood [69].
4.4. Redox Status before and after the HD Treatment. The
hemodialysis treatment can affect patients’ redox status, and
our systematic literature search revealed 11 studies which
examined the possible contribution ofHD treatment to redox
imbalance (Table 3). Three studies indicated that HD treat-
ment per se augments lipid peroxidation, assessed by MDA
[29, 70] and F2-isoprostanes levels [50], and induces protein
damage, assessed by protein carbonylation [53]. However,
there were studies which did not observe any significant
changes in lipid peroxidation (unchanged MDA levels) [71,
72], F2-isoprostanes levels [73], and ox-LDL levels [74]
following the HD process [71–74]. Moreover, in Malindretos
et al.’s study, oxidized LDL levels did not significantly change
after HD treatment, and intravenous iron administration
during HD did not change its concentration following HD
[74].
Regarding antioxidant capacity after completion of HD
therapy, there are conflicting findings. Two studies reported
that the levels of GSH and the activities of GPx and Gr
reductase increased after HD therapy [55, 75]. However,
there were three studies in younger patients which observed
reduced levels of GSH [29, 70], reducedGPx activity [70], and
reduced TAS levels [70, 76] following HD.
Ogunro et al. [70] evaluated the effects of cellulose and
polysulfone membranes, which are the most commonly used
types, on redox status in chronic HD patients. SOD activity
was significantly reduced in both cellulose and polysulfone
membrane dialysis. Regarding other antioxidant biomarkers
evaluated in this study, both types of membranes caused
changes to the same direction but not significantly in all cases.
Specifically, CAT activity was significantly increased only in
polysulfone membrane, while GPx activity was reduced in
both types but not significantly. Additionally, TAS and GSH
levels were significantly reduced after cellulose membrane
HD, while the reductions were not significant in polysulfone
membrane users. Lastly, followingHD treatment,MDA levels
were increased in both types but the change was significant
only in cellulose membrane.
On the other hand, Ward et al. [53] did not find differing
responses to the use of polysulfone or cellulose membranes
on protein oxidation. These HD patients demonstrated
already high plasma protein carbonyls and AOPP concentra-
tions compared to normal values before HD treatment. With
HD, using either membrane, protein carbonyls increased sig-
nificantly over the course of HD and remained significantly
elevated for the postdialysis period, indicating worsening in
protein oxidative damage. Dialysis had no effect on AOPP
levels and their values remained significantly higher thannor-
mal after dialysis. Perhaps counterintuitively, in that study,
following HD a significant increase in plasma free sulfhydryl
groups concentrations was found (levels essentially corrected
to the levels of normal values) for bothmembranes used [53].
Bober et al. [29] assessed the effects of glucose content in
the dialyzing fluid on RBC antioxidant capacity. They found
that glucose concentrations of about 5.6mmol/l resulted in
augmentation of the hexose monophosphate cycle (HMP)
in erythrocytes and accordingly benefited the antioxidant
system. Furthermore, the group that received the glucose-
free HD treatment presented with increased TBARS concen-
tration after the treatment [29]. According to the authors,
this probably occurred because the free radicals produced
during the glucose-free HD session could not be neutralized
through the nonenzymatic pathway at a satisfactory rate [29].
In the cross-sectional study of Dolegowska et al. [50], there
were no significant differences either before or after HD
treatment in 8-iPF2a-III levels in RBC membranes of HD
patients treated with glucose or glucose-free dialyzing fluids.
Still, they reported a significant increase of plasma 8-iPF2-III
concentration followingHD in the glucose-free group (which
however started at amuch lower level than the glucose treated
group).
Various mechanisms have been proposed to account for
the increased oxidative damage following HD treatment:
the issue of hemoincompatibility induced by the contact
between human blood and the nonbiological materials of
the hemodialyzer and the resulting effects on leukocyte and
platelet activation and inflammation [20, 77, 78], systemic
inflammation effects mediated via neutrophil activity burst
resulting in the release of ROS into the bloodstream [46,
56], and the role the HD process per se in reducing plasma
antioxidant defense because several antioxidant dialyzable
solutes are removed during HD.
The role of the type of dialysis membrane used is not
straightforward [53, 71]. This is probably due to the different
reactions that take place in sulfhydryl groups and protein
carbonyl formation. Possibly, protein sulfhydryl groups are
oxidized reversibly through small molecules oxidants, which
can be removed by dialysis process, while AOPP and protein
carbonyls may represent a chronic state of irreversible oxida-
tive damage [53].
With regard to dialyzing fluid composition, it could be
generally concluded that glucose has a beneficial effect on
the antioxidant properties of RBC and protects them by
decreasing the risk for hemolysis [29, 50].
4.5. Interventions in HD Patients and Redox Status. Three
studies examined the effects of vitamin C administration on
redox status of HD patients. Fumeron et al. [77] reported
that oral administration of 250mg vitamin C three times
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per week for two months could not either increase GSH or
reduce protein carbonyls levels. Washio et al. [78] found
that oral administration of vitamin C for 3 months rang-
ing from low (200mg) to high dose (1000mg) could not
suppress the enhancement of Cu/Zn-SOD expression, an
oxidative stress marker. On the other hand, Tarng et al. [79]
found that intravenous administration of 300mg vitamin
C for 8 weeks decreased significantly 8-OHdG contents in
cellular DNA of lymphocytes. Moreover, in the same study,
vitamin C significantly reduced intracellular ROS production
of lymphocytes of patients on HD [79].
Regarding vitamin E, another important antioxidant
substance, Smith et al. [73] examined the effects of 400 IU
administration for 2 months on redox status of 11 HD
patients. The elevated free F2-isoprostane plasma concen-
trations were not decreased by vitamin E supplementation.
Likewise, treatment with a combination ofmixed tocopherols
plus 𝛼-lipoic acid (oral) for 6 months did not change
plasma F2-isoprostane and F2-isofuran of HD patients com-
pared to placebo group as reported by Himmelfarb et al.
[80].
A pilot study by Trimarchi et al. [71] showed that the
daily administration of 1,200mg NAC for one month could
significantly reduce plasma lipid peroxidation of HD patients
compared to the control group. Finally, Fatouros et al. [81]
reported that daily administration of 20mg/kg L-carnitine
in 12 HD patients for 8 weeks resulted in 2,7-fold increased
GSH/GSSG ratio, a 4.5% increase in glutathione peroxidase
activity, a 19% decrease in MDA levels, and 27% decrease in
protein carbonyls concentration.
Vitamin C is one of the most important water-soluble
antioxidants.There is evidence that HD patients exhibit a 30–
50% decrease in vitamin C levels after dialysis treatment, as
reviewed elsewhere [82]. Moreover, reduced vitamin C levels
inHDpatients have been associatedwith an increased risk for
CVDmorbidity andmortality [83]. However, elsewhere, only
intravenous administration was found to have a measurable
beneficial effect [79]. Thus, oral administration of vitamin C
may not be sufficient to correct its deficiency in HD.
Oral administration of vitamin E did not decrease plasma
isoprostanes in HD patients [74, 83]. In contrast, it has been
reported that long-term administration of 200mg of vitamin
E decreased F2-isoprostanes plasma levels in mildly hyper-
cholesterolemic men [84]. Moreover, in healthy subjects,
vitamin E administration resulted in lower F2-isoprostane
concentrations in urinary samples [85]. Perhaps differences
in outcomes relate to dosage and duration of administration
could explain these results, notwithstanding the augmented
oxidant production characterizing HD patients in which
perhaps oral administration of vitamin E, at safe levels for
these patients, could not combat.
N-acetylcysteine (NAC) is a ROS scavenger and its
administration seems to increase glutathione concentration
given that it raises intracellular levels of one of its precursors,
cysteine [86–88]. Along with L-carnitine, these products
showed promising results and should be further examined in
larger patient cohorts.
4.6. Other Types of Dialysis and Redox Status. Our systematic
literature review revealed 4 studies that examined other types
of dialysis in relation to oxidative stress and antioxidant status
biomarkers (Table 4). A metabonomics study by Choi et al.
[30] examined the effects of different dialysis modalities on
serum profiles of patients. XO activity levels were similar
for both HD and peritoneal dialysis (PD) patients. Still XO
activity was significantly higher in PD patients compared to
controls and to nondialyzed uremic patients (non-HDor PD)
[30], perhaps justifying the need to address it pharmaceuti-
cally (see below in Interventions in PD).
In the study of Canestrari et al. [89] erythrocyte GSH
levels were unchanged or slightly increased in the patients
compared to the control group, while a nearly 3-fold increase
in GSSG was observed in the PD group [89]. In the same
study, plasma GSH levels were significantly decreased in the
PD group compared to control group and GSSG levels were
slightly increased in PD patients [89]. Moreover, increased
RBC and plasma TBARS levels were found in PD patients
compared to control group. Finally, significantly higher
erythrocyte GSH-Px activity was observed in the PD group,
while plasma GSH-Px activity was similar in PD patients and
controls [89].
Moreover, a study by Gonza´lez-Diez et al. [90] examined
and compared the effects of haemodiafiltration (HFR) on
HD with polysulfone membranes (HD-PS). The HFR group
demonstrated moderate changes in oxidative stress biomark-
ers and antioxidant capacity markers, indicating that this
method may in the long term preserve a more stable and
balanced redox status compared to HD-PS [90].
4.7. Interventions in PD Patients and Redox Status. Imani et
al. [91] evaluated the effects of soy consumption (28 g/day)
for 8 weeks on oxidative stress in PD patients. Results
indicated no changes in serum ox-LDL between soy and
control groups of PD patients; however, an improvement
in thrombosis risk was reported. The fact that 78% of the
specific peritoneal dialysis patients received vitaminC and/or
E could explain the lack of a measurable effect. We do
consider, however, that such dietary interventions as well as
antioxidant interventions of adjunct pharmaceuticals need
further examination (see below).
Overall, based on the limited data reviewed so far, PD
also appears to be associated with increased oxidative stress,
with Choi et al.’s study [30] showing PD patients to have
as high XO activity as HD patients and Canestrari et al.’s
study [89] showing not only increased oxidative stress but
also evidence of reductions in antioxidant capacity, compared
to controls. As XO is a superoxide producing enzyme its
inhibition has been viewed as a way to reduce CVD risk (e.g.,
via allopurinol, [92]). To circumvent possible allopurinol’s
toxicity in renal insufficiency patients, careful screening
and tolerance protocols are needed [93]. A new nonpurine
alternative, febuxostat, has been shown to reduce serum levels
of uric acid and levels of a marker of DNA oxidation (8-oxo-
dG) following 6-month administration in HD patients [94].
In non-CKD patients, soy consumption has been
reported to improve redox status (e.g., in gestational
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diabetes [95]). Notably, the combination of soy milk with
Lactobacillus plantarum was recently shown not only to
improve redox status, versus consumption of plain soy
milk, but also to exert a promising epigenetic effect on
the DNA repair capability of type II diabetic patients [96].
Dietary antioxidants may play a role even before disease
diagnosis, whether independently or as a component of a
generally “healthy lifestyle,” as increased albuminuria (a
prognostic marker for kidney disease) has been found to be
associated with reduced levels of diet-derived carotenoids
in an indigenous Australia population [97]. Such and other
findings highlight the complexity and overarching effect on
redox status introduced by diet. We suspect that, whether
early in the disease or towards advanced stages (especially
when CKD patients face severe nutritional restrictions
when at the same time not only noxious but also potentially
beneficial antioxidant intermediates may accumulate [98]),
the role of targeted nutritional aids to reduce systemic
oxidative stress could prove to be crucial for the reduction of
CVD and malignancies risk.
Our evaluation of the systemic effects of oxidative stress
in CKD patients does not account for the issue of kidney
tissue and cell specific disturbances in redox homeostasis.
Although beyond the aim of the present systematic review,
we consider it of interest to give some highlights on the
role of kidney injury per se. Initial glomerular injury affects
podocytes, the glomerular visceral epithelial cells, which
constitute not only the target but also the source of ROS.
Bek et al. 2003 [99], using cultured mouse podocytes,
demonstrated that STRA13, a prostaglandin E2-induced gene,
protected the redox homeostasis in this cell type, preventing
podocytes from injuries and subsequent detrimental effects
on kidney functionality. Apart from podocytes, another type
of kidney cells, known as mesangial cells, is known to play
an important role in CKD progression. More specifically,
angiotensin II (ANG II) stimulates proliferation of the
mesangial cells resulting in pathological changes in CKD
[100, 101]. Although the exact mechanism remains incom-
pletely understood, Ding et al. 2007 [102] reported that the
ROS-epidermal growth factor receptor EGFR-JNK pathway
is involved in transducing the proliferative effects of ANG
II in cultured mesangial cells. Thus, specifically targeting
the injured kidney to ameliorate or break the vicious circle
of recurrent injury, inflammation, and oxidative stress and
salvage glomerular function (as suggested in [103]) holds
promise.
5. Conclusions
The results of this systematic review indicate that oxidative
stress is implicated in the CKD pathophysiology and as the
kidney function is getting worse, the redox status imbalance
becomes more profound. Even at an early disease stage, lipid
peroxidation markers are elevated. This premature develop-
ment sets perhaps the pace for accelerated atherogenesis,
which appears to explain the profoundly negative CVD risk
of end stage patients.Thus early interventions to combat lipid
peroxidation in predialysis patients need to be considered.
At the end stage, patients present with both overabun-
dance of ROS and mostly compromised antioxidant capacity.
HD therapy per se seems to contribute to the oxidant and
antioxidant imbalance. Iron supplementation has a proox-
idant role but appears largely balanced out by appropriate
EPO supplementation. The choice of dialysis membrane and
dialyzing fluid glucose content may modulate the prooxi-
dant effect of HD treatment. Moreover, antioxidant supple-
ments may ameliorate oxidative stress levels by enhancing
antioxidants defense; however, mode of administration (i.e.,
intravenous for vitamin C) should be carefully considered for
efficacy. Vitamin E supplementation has been so far shown to
be ineffective in HD patients; however, small studies testing
NAC and L-carnitine reported promising results.
Peritoneal dialysis did not appear to have a clear advan-
tage over HD treatment, despite the biocompatibility advan-
tage, while HFR may better preserve some antioxidant
molecules. However, the small number of studies in PD and
HFR does not allow for safe conclusions and further work is
needed to clarify the role of dialysis modality on redox status
of ESRD patients.
Future studies addressing possible interventions to
reduce the high burden of oxidative stress in patients with
CKD are needed. Such studies should be prospective, com-
parative, and systematically structured according to outcome,
should include a large number of patients, and should have an
adequately long follow-up.
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